Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

The FDA approved Ojjaara for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia.

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

Nurse practitioner Charina Toste explains why it is important for patients to be empowered to have educated conversation with their care teams.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Laura Michaelis, a 2019 CURE MPN Hero, about how far we’ve come in the myeloproliferative neoplasm space.

We took a look back at the most noteworthy and compelling myeloprolifearative neoplasm stories from 2023.

Patients with MPNs can potentially experience long asymptomatic periods, and it’s up to patients and providers to remain vigilant as they monitor and manage symptoms.